BioCentury | Dec 6, 2019
Targets & Mechanisms
Bispecifics and allogeneics steal the spotlight from autologous CAR Ts
...design a bispecific antibody with a reduced risk of CRS and neurotoxicity. The company generated TNB-486...
...antibodies for those that induced CD19-targeted lymphoma destruction while minimizing cytokine release. In preclinical models, TNB-486...
...antibodies for those that induced CD19-targeted lymphoma destruction while minimizing cytokine release. In preclinical models, TNB-486...
